Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic carcinoma. A phase II study.
Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic carcinoma. A phase II study.
复制标题
环磷酰胺、阿霉素和顺铂 (CAP) 在播散性前列腺癌患者中的评价。
DOI：
10.1097/00000421-198506000-00011
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
Al-Sarraf,M
中科院分区：
文献类型：
--
作者：
Drelichman,A;Oldford,J;Al-Sarraf,M
进行了一项前瞻性研究，以评价环磷酰胺、阿霉素和顺铂联合治疗播散性耐药前列腺癌患者的缓解率和毒性。22例患者入组研究：19例可评价缓解。1例患者部分缓解，14例（73%）病情稳定。4例患者出现疾病进展。病情稳定和部分缓解的患者主观症状改善，生存时间明显长于病情进展的患者（58周vs. 22周）（p< 0.03）。毒性主要为血液学毒性，1例患者死于继发于白细胞减少症的败血症。恶心和呕吐为中度至重度，1例患者因此拒绝顺铂治疗。肾毒性可耐受且可逆。缺乏良好的可测量疾病使得推广困难，但是来自动物模型的指针，沿着我们的结果所建议的生物活性，使得这是一个值得考虑的组合，用于在具有可测量疾病的更大人群中进行试验，或者在与更有效的单一药物相比的随机试验中。
A PROSPECTIVE STUDY WAS CONDUCTED to evaluate response rate and toxicity of the combination of cyclo-phosphamide, adriamycin, and cis-platinum in patients with disseminated hormonally resistant prostatic carcinoma. Twenty-two patients were entered in the study: 19 were evaluable for response. One patient achieved partial remission while 14 (73%) had stable disease. Four patients had progressive disease. Patients with stable disease and partial remission had subjective improvement and survived significantly (p< 0.03) longer than patients with progressive disease (58 weeks vs. 22 weeks). Toxicity was mainly hematological, and one patient died from sepsis secondary to leukopenia. Nausea and vomiting was moderate to severe, with one patient refusing cis-platinum for that reason. Renal toxicity was tolerable and reversible. Lack of good measurable disease makes generalization difficult, but pointers from animal models, along with the biological activity suggested by our results, make this a worthwhile combination to be considered for a trial in a larger population with measurable disease or in a randomized trial vs. the more effective single agent.